{"nctId":"NCT00855465","briefTitle":"A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.","startDateStruct":{"date":"2009-02-23","type":"ACTUAL"},"conditions":["Pulmonary Hypertension"],"count":262,"armGroups":[{"label":"Riociguat (Adempas, BAY63-2521)_individual dose titration","type":"EXPERIMENTAL","interventionNames":["Drug: Riociguat (Adempas, BAY63-2521)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Riociguat (Adempas, BAY63-2521)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients with CTEPH either inoperable or with persistent or recurrent PH after surgery.\n\nExclusion Criteria:\n\n* All types of pulmonary hypertension except subtypes 4.1 and 4.2 of the Venice Clinical Classification of Pulmonary Hypertension.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16","description":"6-minute walking distance (6MWD) is a measure for the objective evaluation of a participant's functional exercise capacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":"79.3"},{"groupId":"OG001","value":"-5.5","spread":"84.3"}]}]}]},{"type":"SECONDARY","title":"Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16","description":"The pulmonary vascular resistance (PVR) is a calculated hemodynamic parameter. PVR is derived from the directly measured parameters mean pulmonary arterial pressure (PAPmean) and pulmonary capillary wedge pressure (PCWP), divided by the cardiac output (CO). PVR and PAPmean are acquired during a right heart catheterization. CO is a calculated hemodynamic parameter, too. Formula: PVR = 80\\*(PAPmean - PCWP)/CO","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-225.68","spread":"247.52"},{"groupId":"OG001","value":"23.07","spread":"273.53"}]}]}]},{"type":"SECONDARY","title":"N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) - Change From Baseline to Week 16","description":"N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute congestive heart failure (CHF) and may be useful to establish prognosis in heart failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-290.69","spread":"1716.90"},{"groupId":"OG001","value":"76.35","spread":"1446.63"}]}]}]},{"type":"SECONDARY","title":"World Health Organization (WHO) Functional Class - Change From Baseline to Week 16","description":"The WHO functional assessment of pulmonary arterial hypertension ranged from functional class I (Patients with PH but without resulting limitation of physical activity) to class IV (Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right-heart failure.). Changes to a lower WHO functional class resemble improvement; changes to a higher functional class resemble deterioration of PAH.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":null},{"groupId":"OG001","value":"78.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Worsening","description":"The combined endpoint \"time to clinical worsening\", made up of the following components, defined by the first occurrence: all-cause mortality; heart/lung transplantation; rescue endarterectomy; first hospitalization due to pulmonary hypertension; start of a new pulmonary hypertension treatment; persistent worsening of 6MWD or WHO functional class due to deterioration of PH.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Borg CR 10 Scale - Change From Baseline to Week 16","description":"The Borg CR10 Scale is a participant reported outcome measure used in clinical diagnosis of e.g. breathlessness and dyspnea. It documents the participant's exertion during a physical test. Low values indicate low levels of exertion; high values indicate more intense exertion reported by the participant. The score ranges from 0 (\"Nothing at all\") to 10 (\"Extremely strong - Maximal\").","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"2.39"},{"groupId":"OG001","value":"0.17","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"EQ-5D Utility Score - Change From Baseline to Week 16","description":"EQ-5D utility score is a Quality-of-Life participant reported outcome measure. The utility score is calculated based on five questions concerning problems with mobility, self-care, usual activities, pain/discomfort and anxiety/depression. An increase in the utility score represents an improvement in quality of life. The score ranges from -0.594 (worst answer in all five questions) to 1 (best answer in all five questions).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0615","spread":"0.2768"},{"groupId":"OG001","value":"-0.0819","spread":"0.3446"}]}]}]},{"type":"SECONDARY","title":"Living With Pulmonary Hypertension (LPH) Questionnaire - Change From Baseline to Week 16","description":"The self-reported Living with Pulmonary Hypertension (LPH) questionnaire is designed to measure the effects of PH and PH-specific treatments on an individual's quality of life. The LPH total score can range from 0 (best) to 105 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.72","spread":"18.62"},{"groupId":"OG001","value":"-2.09","spread":"19.31"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"All Caused Mortality","description":"All cause mortality (including cardiovascular mortality) was one component of the composite endpoint \"time to clinical worsening\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Pulmonary Artery Pressure (PAPmean) - Change From Baseline to Week 16","description":"Mean pulmonary arterial pressure (PAPmean) is a directly measured hemodynamic parameter. PAPmean is recorded during a right heart catheterization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.31","spread":"6.70"},{"groupId":"OG001","value":"0.76","spread":"7.26"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cardiac Index (CI) - Change From Baseline to Week 16","description":"The cardiac index (CI) is a calculated hemodynamic parameter. CI is derived from the directly measured parameters cardiac output (CO), divided by the body surface area (BSA). BSA is a calculated parameter, using the subject's height and weight in the DuBois formula. Formula: BSA = (W \\[kg\\]\\*0.425)\\*(H \\[cm\\]\\*0.725)\\*0.007184 (m\\^2)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"0.56"},{"groupId":"OG001","value":"-0.01","spread":"0.58"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Systolic Blood Pressure (SBP) - Change From Baseline to Week 16","description":"Systolic systemic arterial blood pressure (SBP) is a directly non-invasively measured hemodynamic parameter. Range allowed in this study at Visit 0 and/or Visit 1 before randomization: 95 - 180 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.49","spread":"14.17"},{"groupId":"OG001","value":"-5.28","spread":"14.61"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Diastolic Blood Pressure (DBP) - Change From Baseline to Week 16","description":"Diastolic systemic arterial blood pressure (DBP) is a directly non-invasively measured hemodynamic parameter. Range allowed in this study at Visit 0 and/or Visit 1 before randomization: \\<= 110 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.17","spread":"10.81"},{"groupId":"OG001","value":"-3.40","spread":"10.38"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Heart Rate (HR) - Change From Baseline to Week 16","description":"Heart rate (HR) is a directly non-invasively measured hemodynamic parameter. Range allowed in this study at Visit 0 and/or Visit 1 before randomization: 50 -105 beats per minute (bpm) at rest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"11.74"},{"groupId":"OG001","value":"1.67","spread":"12.37"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Alanine Aminotransferase (ALT) - Change From Baseline to Week 16","description":"Alanine Aminotransferase (ALT) is a standard clinical chemistry parameter. Normal range: 0 to 45 U/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"16.2"},{"groupId":"OG001","value":"2.2","spread":"13.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Aspartate Aminotransferase (AST) - Change From Baseline to Week 16","description":"Aspartate Aminotransferase (AST) is a standard clinical chemistry parameter. Normal range: 0 to 41 U/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"14.4"},{"groupId":"OG001","value":"2.8","spread":"12.0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Alkaline Phosphatase (AP) - Change From Baseline to Week 16","description":"Alkaline phosphatase (AP) is a standard clinical chemistry parameter. Normal range: 40 to 129 U/L (males), 35 to 104 U/L (females)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"19.4"},{"groupId":"OG001","value":"2.5","spread":"20.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Bilirubin - Change From Baseline to Week 16","description":"Bilirubin is a standard clinical chemistry parameter. Normal range: 0.1 to 1.2 mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.010","spread":"0.483"},{"groupId":"OG001","value":"0.189","spread":"0.453"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Creatinine - Change From Baseline to Week 16","description":"Creatinine is a standard clinical chemistry parameter. Normal range: 0.25 to 1.20 mg/dL (males), 0.46 to 1.00 mg/dL (females)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":"0.338"},{"groupId":"OG001","value":"0.032","spread":"0.178"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Creatinine Clearance - Change From Baseline to Week 16","description":"Creatinine clearance is a standard clinical chemistry parameter. Normal range: 90 to 140 mL/min (males), 80 to 125 mL/min (females)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.25","spread":"15.53"},{"groupId":"OG001","value":"-0.93","spread":"11.36"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Creatine Kinase (CK) - Change From Baseline to Week 16","description":"Creatine Kinase is a standard clinical chemistry parameter. Normal range: 35 to 232 U/L (males), 26 to 145 U/L (females)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"64.9"},{"groupId":"OG001","value":"5.6","spread":"65.7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Erythrocytes (RBC) - Change From Baseline to Week 16","description":"Erythrocytes (red blood cells, RBC) is a standard clinical hematology parameter. Normal range: 4.6 to 5.8\\*10\\^12 cells/L (males), 4.1 to 5.2\\*10\\^12 cells/L (females)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.39"},{"groupId":"OG001","value":"0.04","spread":"0.31"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Leukocytes (WBC) - Change From Baseline to Week 16","description":"Leukocytes (white blood cells, WBC) is a standard clinical hematology parameter. Normal range: 4.0 to 10.7\\*10\\^9 cells/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.55","spread":"1.77"},{"groupId":"OG001","value":"0.23","spread":"1.69"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Lymphocytes - Change From Baseline to Week 16","description":"Total lymphocytes is a standard clinical hematology parameter. Normal range: 1.0 to 4.0\\*10\\^9 cells/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.48"},{"groupId":"OG001","value":"0.00","spread":"0.53"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Neutrophils - Change From Baseline to Week 16","description":"Neutrophils is a standard clinical hematology parameter. Normal range: 1.6 to 7.4\\*10\\^9 cells/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"1.55"},{"groupId":"OG001","value":"0.26","spread":"1.57"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hemoglobin - Change From Baseline to Week 16","description":"Hemoglobin is a standard clinical hematology parameter. Normal range: 13.5 to 17.5 g/dL (males), 12.0 to 16.0 g/dL (females)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"1.17"},{"groupId":"OG001","value":"0.02","spread":"0.88"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hematocrit - Change From Baseline to Week 16","description":"Hematocrit is a standard clinical hematology parameter. Normal range: 40 to 52% (males), 36 to 46% (females)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"4.1"},{"groupId":"OG001","value":"0.5","spread":"3.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Potassium - Change From Baseline to Week 16","description":"Potassium is a standard clinical chemistry parameter. Normal range: 3.5 to 5.3 mmol/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.48"},{"groupId":"OG001","value":"-0.02","spread":"0.56"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Urate - Change From Baseline to Week 16","description":"Urate is a standard clinical chemistry parameter. Normal range: 4.0 to 8.5 mg/dL (males, 16-59 years), 3.4 to 8.7 mg/dL (males, \\>60 years) 2.5 to 7.5 mg/dL (females)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.405","spread":"1.415"},{"groupId":"OG001","value":"0.209","spread":"1.577"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Urea (BUN) - Change From Baseline to Week 16","description":"Urea (blood urea nitrogen, BUN) is a standard clinical chemistry parameter. Normal range: 4 to 25 mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"15.26"},{"groupId":"OG001","value":"0.99","spread":"13.62"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cystatin C - Change From Baseline to Week 16","description":"Cystatin C is a biomarker. Normal range: 0.53 to 1.01 ng/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":"241.1"},{"groupId":"OG001","value":"62.9","spread":"198.0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Triacylglycerol Lipase - Change From Baseline to Week 16","description":"Triacylglycerol lipase is a standard clinical chemistry parameter. Normal range: 7 to 60 U/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"12.9"},{"groupId":"OG001","value":"0.1","spread":"17.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Arterial Partial Pressure of Carbon Dioxide (PaCO2) - Change From Baseline to Week 16","description":"Arterial partial pressure of carbon dioxide (PaCO2) is performed as part of the capillary or arterial blood gas analysis. If possible, no supplementary oxygen was given during the resting period and while blood samples were drawn.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"4.05"},{"groupId":"OG001","value":"0.56","spread":"4.52"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Arterial Partial Oxygen Pressure (PaO2) - Change From Baseline to Week 16","description":"Arterial partial pressure of oxygen (PaO2) is performed as part of the capillary or arterial blood gas analysis. If possible, no supplementary oxygen was given during the resting period and while blood samples were drawn.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.01","spread":"14.71"},{"groupId":"OG001","value":"-4.95","spread":"12.05"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Oxygen Saturation (SaO2) - Change From Baseline to Week 16","description":"Oxygen saturation (SaO2) is measured as part of the capillary or arterial blood gas analysis. Normal blood oxygen saturation is considered 95-100 percent. If possible, no supplementary oxygen was given during the resting period and while blood samples were drawn.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"4.4"},{"groupId":"OG001","value":"-3.1","spread":"8.0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean PR Duration (PRmean) - Change From Baseline to Week 16","description":"PR duration was evaluated as part of the 12-lead electrocardiogram. electrocardiograms (ECGs) were recorded after the participant had been at rest for 15 minutes in a supine position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"14.21"},{"groupId":"OG001","value":"0.87","spread":"11.16"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean QRS Duration (QRSmean) - Change From Baseline to Week 16","description":"QRS duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"4.49"},{"groupId":"OG001","value":"-0.05","spread":"4.30"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean QT Duration (QTmean) - Change From Baseline to Week 16","description":"QT duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"24.89"},{"groupId":"OG001","value":"-2.00","spread":"25.56"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean QTcB Duration (Bazett's Correction Formula, QTcB) - Change From Baseline to Week 16","description":"Bazett-corrected QTcB duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.30","spread":"14.44"},{"groupId":"OG001","value":"-0.51","spread":"15.58"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean QTcF Duration (Fridericia's Correction Formula, QTcF) - Change From Baseline to Week 16","description":"Fridericia-corrected QTcF duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.34","spread":"13.71"},{"groupId":"OG001","value":"-1.02","spread":"13.29"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean RR Duration (RRmean) - Change From Baseline to Week 16","description":"RR duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.89","spread":"132.02"},{"groupId":"OG001","value":"-14.00","spread":"131.93"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Ventricular Rate (VRmean) - Change From Baseline to Week 16","description":"Ventricular rate was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.70","spread":"11.96"},{"groupId":"OG001","value":"1.60","spread":"11.68"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":173},"commonTop":["Headache","Dizziness","Oedema peripheral","Dyspepsia","Nasopharyngitis"]}}}